JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first oral PDE4B inhibitor with antifibrotic and immunomodulatory effects authorized for use in IPF and PPF, and the first new treatment in […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.